Proteomics

Dataset Information

0

Influenza-derived peptide presentation by HLA-A*24:02

ABSTRACT: Identification of influenza virus-derived peptides presented by Human Leukocyte Antigen (HLA) molecules of the C1R (Class I reduced) B-lymphoblastoid cell line, transfected with the HLA class I allele HLA-A*24:02, after influenza infection.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Suspension Culture

SUBMITTER: Patricia Illing  

LAB HEAD: Anthony W Purcell

PROVIDER: PXD020292 | Pride | 2021-04-08

REPOSITORIES: Pride

Json Xml
altmetric image

Publications

CD8<sup>+</sup> T cell landscape in Indigenous and non-Indigenous people restricted by influenza mortality-associated HLA-A*24:02 allomorph.

Hensen Luca L   Illing Patricia T PT   Bridie Clemens E E   Nguyen Thi H O THO   Koutsakos Marios M   van de Sandt Carolien E CE   Mifsud Nicole A NA   Nguyen Andrea T AT   Szeto Christopher C   Chua Brendon Y BY   Halim Hanim H   Rizzetto Simone S   Luciani Fabio F   Loh Liyen L   Grant Emma J EJ   Saunders Phillipa M PM   Brooks Andrew G AG   Rockman Steve S   Kotsimbos Tom C TC   Cheng Allen C AC   Richards Michael M   Westall Glen P GP   Wakim Linda M LM   Loudovaris Thomas T   Mannering Stuart I SI   Elliott Michael M   Tangye Stuart G SG   Jackson David C DC   Flanagan Katie L KL   Rossjohn Jamie J   Gras Stephanie S   Davies Jane J   Miller Adrian A   Tong Steven Y C SYC   Purcell Anthony W AW   Kedzierska Katherine K  

Nature communications 20210518 1

Indigenous people worldwide are at high risk of developing severe influenza disease. HLA-A*24:02 allele, highly prevalent in Indigenous populations, is associated with influenza-induced mortality, although the basis for this association is unclear. Here, we define CD8<sup>+</sup> T-cell immune landscapes against influenza A (IAV) and B (IBV) viruses in HLA-A*24:02-expressing Indigenous and non-Indigenous individuals, human tissues, influenza-infected patients and HLA-A*24:02-transgenic mice. We  ...[more]

Similar Datasets

Proteomics Influenza B-derived peptide presentation by HLA-B*07:02, -B*08:01 and -B*35:01
2024-03-04 | PXD045000 | Pride
Proteomics Influenza-derived peptide presentation by HLA-A*11:01
2022-02-15 | PXD028985 | Pride
Proteomics C1R.B*57:01 MHC class I immunopeptidome LC-MSMS
2018-10-24 | PXD008570 | Pride
Proteomics C1R.B*57:03 MHC class I immunopeptidome LC-MSMS
2018-10-24 | PXD008571 | Pride
Proteomics C1R.B*58:01 MHC class I immunopeptidome LC-MSMS
2018-10-24 | PXD008572 | Pride
Proteomics C1R.A*01:01, C1R.A*02:01, C1R.A*24:02 MHC class I immunopeptidome LC-MSMS
2020-07-27 | PXD014754 | Pride
Proteomics Impact of abacavir and abacavir analogues on HLA-B*57:01 peptide presentation
2019-10-03 | PXD015398 | Pride
Proteomics Impacts of HLA-B57 micropolymorphism (MRM)
2018-10-24 | PXD009850 | Pride
Proteomics HLA-B*15:02 peptide presentation in the presence of carbamazepine and related molecules
2021-03-23 | PXD023545 | Pride
Proteomics The HLA ligandome comprises a limited repertoire of O-GlcNAcylated antigens preferentially associated with HLA-B07:02
2021-12-03 | PXD028874 | Pride